A Study of CDX-622 in Participants With Mild to Moderate Asthma
Recruiting now · Phase 1
Conditions studied: Mild to Moderate Asthma
In brief
This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.
Key facts
- Study ID
- NCT07330778
- Run by
- Celldex Therapeutics
- People needed
- 12
- Starts
- 2026-06-01
- Expected to finish
- 2027-03-01
- Last updated by the study team
- 2026-07-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California, San Francisco — San Francisco, California, United States (enrolling)
- The University of Kansas Medical Center — Kansas City, Kansas, United States (enrolling)
- Brigham and Women's Hospital — Boston, Massachusetts, United States (enrolling)
- University of Pittsburgh Asthma and Environmental Lung Health Institute at UPMC — Pittsburgh, Pennsylvania, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.